1039819-74-3

Basic information

• Product Name: 3-(2,6-difluorophenyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline
• Synonyms: 3-(2,6-difluorophenyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline
• CAS NO: 1039819-74-3
• Molecular Weight: 290.293
• Mol File: 1039819-74-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-(2,6-difluorophenyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,6-difluorophenyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline(1039819-74-3)
• EPA Substance Registry System: 3-(2,6-difluorophenyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline(1039819-74-3)

Safety Data

• Hazardous Substances Data: 1039819-74-3(Hazardous Substances Data)

Upstream product

• 207974-17-2 2,6-difluorophenylisothiocyanate 
• 134-20-3 2-carbomethoxyaniline 

Relevant articles and documents

USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES

The present invention relates to the use of a series of compounds derived from quinazoline for the production of a drug for treating and/or preventing neurological and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. The present invention also relates to a method for treating and/or preventing neurological and neurodegenerative diseases, consisting in administering a therapeutically effective amount of said compounds.

Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model

A simple and efficient synthetic method for the preparation of quinazoline type phosphodiesterase 7 (PDE7) inhibitors, based on microwave irradiation, has been developed. The use of this methodology improved yields and reaction times, providing a scalable procedure. These compounds are pharmacologically interesting because of their in vivo efficacy both in spinal cord injury and Parkinson's disease models, as shown in previous studies from our group. Herein we describe for the first time that administration of one of the PDE7 inhibitors here optimized, 3-phenyl-2,4-dithioxo-1,2,3,4-tetrahydroquinazoline (compound 5), ameliorated brain damage and improved behavioral outcome in a permanent middle cerebral artery occlusion (pMCAO) stroke model. Furthermore, we demonstrate that these PDE7 inhibitors are potent anti-inflammatory as well as neuroprotective agents in primary cultures of neural cells. These results led us to propose PDE7 inhibitors as a new class of therapeutic agents for neuroprotection.